Desoxycorticosterone pivalate-salt treatment leads to non-dipping hypertension in Per1 knockout mice

K Solocinski1,2, M Holzworth1, X Wen1

  • 1Department of Medicine, University of Florida, Gainesville, FL, USA.

Abstract

Insights

Loss of the PER1 gene disrupts blood pressure regulation, causing a dangerous lack of dipping during rest in mice on a high salt diet. This highlights PER1

Area of Science:

  • Circadian Biology
  • Cardiovascular Physiology
  • Molecular Medicine

Background:

  • Circadian clock proteins regulate physiological functions, including blood pressure.
  • Absence of a blood pressure dip during rest is a cardiovascular disease risk factor.
  • PER1 is a key circadian clock protein implicated in blood pressure regulation.

Purpose of the Study:

  • To investigate the role of PER1 in blood pressure regulation under high salt and mineralocorticoid conditions.
  • To determine the effects of a high salt diet plus mineralocorticoid on PER1-mediated blood pressure control in C57BL/6J mice.

Main Methods:

  • Radiotelemetry was used to measure blood pressure in wild-type (WT) and Per1 knockout (KO) mice.
  • Mice were subjected to a high salt diet (4% NaCl) and deoxycorticosterone pivalate.
  • Blood pressure and activity rhythms were analyzed to assess changes over time.

Main Results:

  • High salt and mineralocorticoid treatment did not affect blood pressure in WT mice.
  • Per1 KO mice showed significantly increased mean arterial pressure (MAP) under treatment.
  • Per1 KO mice lost their normal blood pressure dip during the inactive phase, exhibiting a non-dipper phenotype.

Conclusions:

  • Loss of PER1 enhances sensitivity to high salt and mineralocorticoid-induced hypertension.
  • PER1 deficiency leads to a non-dipper phenotype, a marker for cardiovascular risk.
  • The circadian clock protein PER1 plays a crucial role in modulating blood pressure in response to high salt and mineralocorticoid challenges.

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
3.0K